Replies to post #7474 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

The phrase “you can lead a horse to water, but you can't make it drink” is a proverb that means you can provide someone with a great opportunity, but you can't force them to take it if they don't want to.



https://knowyourphrase.com/you-can-lead-a-horse-to-water

I respect your opinion, I just see no basis for it.

I mean, you don't say much to provide further dialog.

Rarely do I post one liners to get a point across.

Oh, a "decent amount of shares" is subjective.

What you may consider decent someone else may consider paltry.

Perception is your reality.

Hence, you feel (not us) lucky to see a dollar.

Unplug.

0101010101010101010

/////AMG

[Money $hot]

Hey Eagle. When is the last time you gave the corporate presentation (dated 1st Quarter 2020) a look?

On page 23 Algernon shows a comparison to Chronic Cough within the industry.

They mention the 2 companies Algernon is going head up against.

BELLUS Health and Merck.

In the illustration below, you see Merck bought the chronic cough drug for USD $1.2B

You're also aware of the fact, Algernon's NP-120 Ifenprodil for Chronic Cough outperformed Merck by 110%.

I assure you there can't be too many people that shares your view of $1 per share max.

That gives Algernon a market cap of USD $100M.

IMO, that's just willy nilly math.

Corporate Presentation - Page 23

algernonpharmaceuticals.com/wp-content/uploads/2018/01/Algernon-1st-Quarter-2020.pdf


/////AMG

[medchem]

Science doesn't care about share price predictions.

NMDA antagonist. Patented for respiratory disease. Shown to decrease mortality >40% for acute lung injury and acute respiratory distress syndrome, same as COVID causes. Global demand, people dying around the world; people need a therapy now. Algernon has a safe one.

NMDA antagonist alters immune response, decrease neuronal hyperexcitability. Decrease glutamate excess. Save the neurons. Save the T cells. Save the pulmonary capillary endothelium. Save lives.

Better than the best big pharma has to offer.

Watch what happens when they get trial approval this week.

People like you always show up once penny's run. Love showing up trying to short. Can see right through it. Shorts will get wrecked upon the news drop. Could come any minute.